Adriana Nancy Medeiros Dos Santos1,2, Guilherme Amorim Avilla Gimenez Junior3, Isabela M Benseñor4,5, Alessandra C Goulart4,5, Andre R Brunoni4,5,6, Maria Carmen Viana7, Paulo A Lotufo4,5, Claudia Kimie Suemoto5,8. 1. Department of Internal Medicine, University of Sao Paulo Medical School, São Paulo, Brazil. adriana.nancy.medeiros@usp.br. 2. Center for Clinical and Epidemiological Research, University of São Paulo, São Paulo, SP, Brazil. adriana.nancy.medeiros@usp.br. 3. Department of Experimental Pathophysiology, University of Sao Paulo Medical School, São Paulo, Brazil. 4. Department of Internal Medicine, University of Sao Paulo Medical School, São Paulo, Brazil. 5. Center for Clinical and Epidemiological Research, University of São Paulo, São Paulo, SP, Brazil. 6. Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo Medical School, São Paulo, Brazil. 7. Department of Social Medicine, Center of Psychiatric Epidemiology (CEPEP), Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitória, Brazil. 8. Division of Geriatrics, University of Sao Paulo Medical School, São Paulo, Brazil.
Abstract
OBJECTIVES: Using multiple drugs with anticholinergic properties is common and might lead to cumulative anticholinergic toxicity and increased risk of cognitive impairment. Therefore, we sought to investigate the association between the Anticholinergic Cognitive Burden (ACB) Scale and cognitive performance among middle-aged and older adults. METHODS: In this cross-sectional study with 13,065 participants from the baseline visit of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), mean age was 51.7 ± 9.0 years old, 55% women, and 53% white. The ACB was calculated based on the medications in use. We investigated the association of ACB with global cognition and memory, verbal fluency (VF), and trail-making test version B (TMT-B) z-scores, using multiple linear regression models adjusted for sociodemographic and clinical variables. RESULTS: Overall, 16% of participants had an ACB score greater than 0. ACB was associated with poor cognitive performance in all tests in crude analysis. After adjustment for sociodemographic characteristics, the association remained significant for the global cognitive score, as well as the memory and the TMT-B z-scores. However, after further adjustments for clinical variables, only trend associations of ACB with poor memory (β = - 0.02, 95% Cl = - 0.05, 0.00, p = 0.056) and the TMT-B z-scores (β = - 0.02, 95% Cl = - 0.04, 0.00, p = 0.054) were found. In stratified analyses by age groups, ACB was associated with poor cognitive performance on the TMT-B (β = - 0.03, 95% Cl = - 0.05, - 0.01, p = 0.005) in individuals aged less than 65 years old. CONCLUSION: Although the ACB was associated with poor executive function only among middle-aged adults in adjusted analysis, residual confounding may partly explain our results.
OBJECTIVES: Using multiple drugs with anticholinergic properties is common and might lead to cumulative anticholinergic toxicity and increased risk of cognitive impairment. Therefore, we sought to investigate the association between the Anticholinergic Cognitive Burden (ACB) Scale and cognitive performance among middle-aged and older adults. METHODS: In this cross-sectional study with 13,065 participants from the baseline visit of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), mean age was 51.7 ± 9.0 years old, 55% women, and 53% white. The ACB was calculated based on the medications in use. We investigated the association of ACB with global cognition and memory, verbal fluency (VF), and trail-making test version B (TMT-B) z-scores, using multiple linear regression models adjusted for sociodemographic and clinical variables. RESULTS: Overall, 16% of participants had an ACB score greater than 0. ACB was associated with poor cognitive performance in all tests in crude analysis. After adjustment for sociodemographic characteristics, the association remained significant for the global cognitive score, as well as the memory and the TMT-B z-scores. However, after further adjustments for clinical variables, only trend associations of ACB with poor memory (β = - 0.02, 95% Cl = - 0.05, 0.00, p = 0.056) and the TMT-B z-scores (β = - 0.02, 95% Cl = - 0.04, 0.00, p = 0.054) were found. In stratified analyses by age groups, ACB was associated with poor cognitive performance on the TMT-B (β = - 0.03, 95% Cl = - 0.05, - 0.01, p = 0.005) in individuals aged less than 65 years old. CONCLUSION: Although the ACB was associated with poor executive function only among middle-aged adults in adjusted analysis, residual confounding may partly explain our results.
Authors: Estela M L Aquino; Sandhi Maria Barreto; Isabela M Bensenor; Marilia S Carvalho; Dóra Chor; Bruce B Duncan; Paulo A Lotufo; José Geraldo Mill; Maria Del Carmen Molina; Eduardo L A Mota; Valéria Maria Azeredo Passos; Maria Inês Schmidt; Moyses Szklo Journal: Am J Epidemiol Date: 2012-01-10 Impact factor: 4.897
Authors: Dóra Chor; Márcia Guimarães de Mello Alves; Luana Giatti; Nágela Valadão Cade; Maria Angélica Nunes; Maria del Carmen Bisi Molina; Isabela M Benseñor; Estela M L Aquino; Valéria Passos; Simone M Santos; Maria de Jesus Mendes da Fonseca; Letícia Cardoso de Oliveira Journal: Rev Saude Publica Date: 2013-06 Impact factor: 2.106
Authors: Francesco Landi; Giuseppina Dell'Aquila; Agnese Collamati; Anna Maria Martone; Giovanni Zuliani; Beatrice Gasperini; Paolo Eusebi; Fabrizia Lattanzio; Antonio Cherubini Journal: J Am Med Dir Assoc Date: 2014-10-03 Impact factor: 4.669
Authors: Maria Inês Schmidt; Bruce B Duncan; José Geraldo Mill; Paulo A Lotufo; Dóra Chor; Sandhi Maria Barreto; Estela M L Aquino; Valéria Maria Azeredo Passos; Sheila M A Matos; Maria del Carmen B Molina; Marilia S Carvalho; Isabela M Bensenor Journal: Int J Epidemiol Date: 2014-02-27 Impact factor: 7.196